Last reviewed · How we verify
NCT03863171
Early Diagnosis for Ocular Ischemia Syndrome Using Arterial Spin Labeling Magnetic Resonance Imaging Technique
trial testing Arterial spin labeling (ASL) magnetic resonance imaging in Ocular Ischemia Syndrome in 190 participants. Status unknown.
1 March 2020
Quick facts
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 190 |
| Start date | 1 March 2019 |
| Primary completion | 1 March 2020 |
| Estimated completion | 1 March 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Arterial spin labeling (ASL) magnetic resonance imaging
- Fundus fluorescein angiography
Conditions studied
- Ocular Ischemia Syndrome — all drugs for Ocular Ischemia Syndrome →
Sponsor
Beijing Friendship Hospital
Who can join
Adults 50 to 80, any sex, with Ocular Ischemia Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. To evaluate ocular blood perfusion status and the possibility of craniocerebral vascular lesions of patients with ocular ischemia syndrome (OIS) using arterial spin labeling (ASL) magnetic resonance imaging technique. 2. To evaluate the specificity, sensitivity and accuracy of arterial spin labeling (ASL) magnetic resonance imaging technique in OIS diagnosis, compared with the traditional routine examination method.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03863171
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Beijing Friendship Hospital trials
Trials by the same sponsor.
- NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
- NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
- NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
- NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03863171 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
- Last refreshed: 14 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03863171.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing